SEC 13F Intelligence

Managers / Q2 2022 · view latest →

Parian Global Management LP

CIK 0001752148 · 61 POUND RIDGE ROAD, POUND RIDGE, NY, 10576 · 212-466-6961

Reported Value
$22M
Q2 2022
Positions
12
Filings on Record
16
2019–present window
Filed
Aug 15, 2022
original filing

Summary

Parian Global Management LP reported $22M in U.S.-listed holdings across 12 positions for Q2 2022.

Its largest position, Vapotherm, represents 15.9% of the portfolio.

Compared with Q1 2022, the fund opened 1 new position and exited 1.

Portfolio Metrics

Turnover
+4.0%
vs prior filed quarter
Top-10 Concentration
+92.1%
share of reported value
Largest Position
+15.9%
Vapotherm
New / Exited
1 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $144MQ1 ’19Q2 ’19: $154MQ3 ’19: $221MQ3 ’19Q4 ’19: $445MQ1 ’20: $284MQ1 ’20Q2 ’20: $383MQ3 ’20: $315MQ3 ’20Q4 ’20: $400MQ1 ’21: $219MQ1 ’21Q2 ’21: $233MQ3 ’21: $143MQ3 ’21Q4 ’21: $125MQ1 ’22: $49MQ1 ’22Q2 ’22: $22MQ3 ’22: $31MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 79.7%Other: 15.9%ADR: 4.4%
  • Common Stock · 79.7% · $17M
  • Other · 15.9% · $3M
  • ADR · 4.4% · $970,000

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NTRANATERA INCNEW+22.4K22.4K+$794,000$794,000
IRTCIRHYTHM TECHNOLOGIES INCADDED+9.1K17.0K+$597,000$2M
ADMAADMA BIOLOGICS INCSOLD OUT−315.0K0−$576,000$0
TOITHE ONCOLOGY INSTITUTE INCTRIMMED−260.4K183.8K−$2M$930,000
STIMNEURONETICS INCTRIMMED−238.0K718.0K−$593,000$2M
SERASERA PROGNOSTICS INCTRIMMED−209.1K720.0K−$2M$1M
STXSSTEREOTAXIS INCADDED+117.7K724.9K−$931,000$1M
ATECALPHATEC HLDGS INCTRIMMED−39.0K193.8K−$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

12 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1VAPOTHERM INCCOM15.85%$3M1.37M
2CVRXCVRX INChistory →COM14.60%$3M530.4K
3APOLLO ENDOSURGERY INCCOM12.25%$3M733.0K
4STIMNEURONETICS INChistory →COM10.55%$2M718.0K
5BERKELEY LTS INCCOM8.68%$2M381.5K
6IRTCIRHYTHM TECHNOLOGIES INChistory →COM8.43%$2M17.0K
7STXSSTEREOTAXIS INChistory →COM NEW6.11%$1M724.9K
8ATECALPHATEC HLDGS INChistory →COM NEW5.80%$1M193.8K
9SERASERA PROGNOSTICS INChistory →CLASS A COM5.41%$1M720.0K
10RENALYTIX PLCADS4.44%$970,000395.9K
11TOITHE ONCOLOGY INSTITUTE INChistory →COM4.26%$930,000183.8K
12NTRANATERA INChistory →COM3.64%$794,00022.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$31M32Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$22M12Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$49M12May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$125M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$143M32Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$233M44Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$219M34May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020REVEALED$400M54Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$315M31Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$383M36Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$284M37May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$445M44Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$221M30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$154M17Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$144M17May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.